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Inflammatory myofibroblastic tumors (IMTs) occur primarily in visceral and soft tissue of children and young adults and occur most frequently in the first two decades of life. The most common localizations of IMTs have been reported in lung, mesentery and omentum \[[@B1], [@B2]\]. The etiology of IMT is unknown, although infection by Epstein-Barr virus or human herpesvirus-8 and reactive IL-6 production have been observed in a number of cases and discussed as etiological factors \[[@B2], [@B3]\]. A localization of IMT in the pancreas is very rare and needs differentiation from pancreatic head enlargement due to chronic pancreatitis and pancreatic cancer.

The macroscopic appearance of IMT is usually a well-circumscribed or multinodular, white, firm mass with a whorled fleshy cut surface \[[@B2]\]. Histologically, IMT is composed of spindle-shaped myofibroblasts or fibroblasts accompanied by a mixed inflammatory infiltrate of eosinophils, plasma cells, and lymphocytes \[[@B1], [@B2]\]. Necrosis, a central scar, osseous metaplasia, and psammomatous calcifications have been described. The symptoms of IMT are determined by the tumor site. If localized in the pancreatic head with obstruction of the main pancreatic duct, it results in acute and finally chronic obstructive pancreatitis. It is a condition that needs to be differentiated from pancreatic head enlargement due to chronic pancreatitis and pancreatic cancer.

Here we present the case of a young male patient with a history of recurrent acute pancreatitis caused by an IMT of the pancreatic head. In contrast to most reported cases, surgical resection was not possible and a palliative therapeutic regimen including radiation therapy as well as antiinflammatory treatment was established with a regular follow-up of 12 months.

Case Report {#sec1_2}
===========

A 44-year-old male presented to our outpatients department with a two-year history of recurrent acute pancreatitis of unknown etiology. He complained about recurrent upper abdominal pain, intermittent diarrhea, nausea, recurrent emesis and weight loss of 40 kg in the course of the last year. His family history was negative for any pancreatic or malignant disease.

The patient\'s past medical history had been inconspicuous until April 2006 when he was admitted to a regional hospital because of recurrent abdominal pain and jaundice. A first ERCP in that hospital revealed a stenosis of the distal common bile duct and a small concrement proximal to the stenosis. After endoscopic papillotomy and concrement extraction an endoprosthesis was inserted. The pancreatic duct was not visualized. In June 2006, the patient was scheduled for an elective surgical procedure because of the common bile duct stenosis of unknown etiology. A cholecystectomy was performed as there was cholecystolithiasis and a biliodigestive anastomosis was created revealing chronic inflammation of the resected common bile duct. The histological specimen of the common bile duct showed chronic granulomatous inflammation with low-grade dysplasia.

Recurrent attacks of abdominal pain, nausea and emesis in the following months finally led to referral to the department of gastroenterology. Transabdominal ultrasound (**fig. [1](#F1){ref-type="fig"}**) revealed an echo-poor hypovascularized lesion in the pancreatic head, 60 × 40 mm in size, with a dilated main pancreatic duct up to 6 mm in the pancreatic corpus. Additionally, multiple peripancreatic lymph nodes 8--10 mm in diameter were depicted in the peripancreatic mesenterium. Laboratory results showed a 9-fold increase of lipase in combination with elevated markers of cholestasis and slightly elevated transaminases. The concentration of IgG-4 was below the normal range. Blood cell count, coagulation tests and C-reactive protein were within normal ranges. Exocrine pancreatic insufficiency was diagnosed by repeated measurements of pancreatic elastase in the stool and confirmed by ^13^C-mixed-triglyceride breath test. Endocrine pancreatic insufficiency was ruled out. Contrast-enhanced CT scan (**fig. [2a](#F2){ref-type="fig"}**) confirmed the findings of the transabdominal ultrasound with inhomogeneous pancreatic parenchyma in the pancreatic head, a hypodense lesion of almost 3 cm in size within the pancreatic head closely adjacent to the neighboring anatomic structures such as the portal vein, and a dilated main pancreatic duct in the pancreatic corpus and tail. Multiple lymph nodes with a maximum size of 24 mm were depicted in close neighborhood of the organ. There were no focal lesions in the hepatic parenchyma and no intrahepatic cholestasis.

With a suspicion of malignant pancreatic head enlargement, the patient underwent surgery. Intraoperatively, the pancreatic head presented as a hard mass. The pancreatic body and tail showed fibrosis but less distinct than within the pancreatic head. Circumscribed necrosis of pancreatic parenchyma was visible. Preparation of the portal vein was not possible due to massive peripancreatic inflammation and multiple adhesions. As resection of the pancreatic head was technically impossible, a pancreaticogastrostomy was performed.

Histological examination (**fig. [3](#F3){ref-type="fig"}**) showed an IMT with compact fascicular proliferation of spindled and plump myofibroblasts and fibroblasts. The biopsy contained myxoid, edematous, and collagenized regions as well as a distinctive inflammatory infiltrate of lymphocytes, plasma cells and eosinophils. Spindled cells showed a strong expression of cytoplasmatic vimentin and sm actin whereas immunreactivity of desmin, S100, cytokeratin, CD117, or ALK was not observed. Necrosis, cellular atypia, mitotic figures, or overexpression of p53 were not evident in the tissue. Histology was consistent with the diagnosis of an IMT. The adjacent pancreatic tissue was partly displaced by proliferating fibroblasts and collagen deposits. More distantly, there were periductular fibrosis and a scattered infiltrate of lymphocytes and histiocytes of the pancreatic tissue, leading to the diagnosis of chronic pancreatitis. No histological evidence of autoimmune pancreatitis was present.

The short-term postoperative course was unremarkable. After a follow-up of 3 months, the patient presented with aggravating abdominal pain and weight loss of 10 kg despite pancreatic enzyme supplementation. CT scan after another 6 months (fig. [2b](#F2){ref-type="fig"}) revealed a large tumor mass comprising the pancreatic head, liver hilus and mesenteric vessels. Symptomatically, the patient complained about non-infectious diarrhea due to exocrine pancreatic insufficiency and ischemic condition presenting with typical ischemic left colonic lesions and ischemic duodenitis. Lacking evidence-based guidelines, we decided to perform radiation therapy (20/2 Gy) and antiinflammatory medical therapy starting with 60 mg prednisolone per day that was tapered down. After another 3 months, the patient presented well-being in our outpatient department. Pain was symptomatically treated and controlled with novaminsulfon and a low-potent opioid (tramadol), stool frequency was stable and he gained 8 kg of weight. CT scan showed at least a stable tumor mass (fig. [2c](#F2){ref-type="fig"}) and the patient was scheduled for follow-up.

Discussion {#sec1_3}
==========

In case of recurrent acute pancreatitis of unknown etiology and echo-poor pancreatic head enlargement, ductal adenocarcinoma is always an important differential diagnosis. Clinically and morphologically, the very rare IMT resembles pancreatic adenocarcinoma as well as inflammatory lesions related to autoimmune pancreatitis or malignant fibrous histiocytoma.

For several decades the term 'inflammatory pseudotumor' summarized a wide range of reactive and neoplastic lesions. During the last decade the diagnosis and characterization of IMT has been optimized by distinct pathological and molecular features. The World Health Organization classifies this rare tumor entity as a distinctive neoplasm of intermediate biological potential \[[@B4]\]. Especially the discovery of cytogenetic aberrations in IMT and the recognition of ALK gene rearrangements solidified the concept of IMT as a neoplastic lesion \[[@B5]\]. It most frequently occurs in the lung or the mesenterium of children or young adults and rarely (\<5%) metastasizes \[[@B5], [@B6]\].

In a large study of IMTs by Coffin et al. \[[@B2]\], extrapulmonary IMTs were described to be larger and less well-circumscribed than pulmonary IMTs. Adjacent organs are more often involved, which reduces the opportunity for complete resection and leads to a recurrence rate of approximately 25% related to resectability, multinodularity, and location.

Only 28 cases of pancreatic IMT have been reported so far \[[@B7], [@B8]\], 60% being located in the pancreatic head (**table [1](#T1){ref-type="table"}**). Histological diagnosis in biopsies or intraoperative frozen sections is difficult and IMTs must be differentiated from inflammatory pseudotumors due to autoimmune pancreatitis \[[@B9]\] or chronic pancreatitis, fibrosarcoma, pancreatic carcinoma and lymphoma \[[@B10]\], as their therapies differ substantially. The low incidence of IMT of the pancreas and the synonymous use of the terms IMT and inflammatory pseudotumor make it even more difficult to give consistent information on epidemiology, clinical presentation and prognosis of this tumor entity.

Here we report the case of a young male with a history of chronic pancreatitis due to recurrent episodes of acute pancreatitis caused by an IMT in the pancreatic head. In contrast to the majority of cases in the literature (table [1](#T1){ref-type="table"}), curative resection was impossible. The two-year history of recurrent attacks of acute pancreatitis and of a stenosis of the common bile duct with histopathologic signs of chronic inflammation leads to the assumption that the tumor developed over a longer period of time.

Besides surgical resection, alternative therapeutic regimes are still lacking. While systemic immunosuppressive treatment with steroids has been reported for extrapancreatic IMTs, there is only one reported case of IMT localized in the pancreatic head in a pediatric patient \[[@B11]\] that was treated with a palliative approach. In our patient we decided to perform palliative radiation for local tumor treatment combined with antiinflammatory medical treatment as an individualized approach. The patient has been included in a regular follow-up of 12 months up to now. Radiation therapy and corticoid medication might be discussed for alternative and symptomatic treatment but cannot be recommended as a standard regimen for palliative therapy. Close follow-up and symptomatic therapy are the basic therapeutic modalities that hopefully can be complemented by an effective medical therapy in future.
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![Transabdominal ultrasound (Philips, 2D 35 Hz) revealing an echo-poor pancreatic head enlargement (1) and consecutive dilatation of the pancreatic duct (pd). The pancreatic tail presented with unsuspicious parenchyma, whereas small calcifications (c) were visible in the pancreatic head.](crg0004-0443-f01){#F1}

![CT scan images documenting tumor size and spread (1) at diagnosis (**a**), 6 months after diagnosis (**b**) and another 3 months after radiation and corticoid therapy (**c**). At diagnosis, consecutive dilatation of the pancreatic duct (pd) was visible secondary to the pancreatic head enlargement. CT scan did not reveal typical morphological signs of advanced chronic pancreatitis \[pancreatic parenchyma (p) and splenic artery and vein (sa)\]. Follow-up after 3 months (**b**) presented a diffuse tumor mass comprising the pancreatic head, liver and mesenteric arteries. After radiation and corticoid therapy (**c**), a partial response of the tumor mass was visible. No metastases were detected.](crg0004-0443-f02){#F2}

![Panels of H&E staining (**a**) and immunohistochemical staining of vimentin (**b**) and LCA (leukocytic common antigen; CD45) (**c**) demonstrating replacement of the pancreatic tissue (P) by IMT with compression of the ductuli (D, →), fibrosis (F) and sparse infiltration of lymphocytes. High magnification showed a compact spindle proliferation with fascicular and storiform pattern (**d**) and a polymorphous inflammatory infiltrate with predominant eosinophils (**g**, →), lymphocytes (**h**), and plasma cells (**i**). Biopsy of the duodenum showed ischemic changes with irregularity, atrophy and regenerative atypies of the epithelium (**j**). Spindle cells showed diffuse cytoplasmatic immunoreactivity of vimentin (**b**, **e**) and sm actin (**f**) (microscope: Zeiss Axioscope 50, camera: Nikon coolpix 990; magnification: ×200, ×400).](crg0004-0443-f03){#F3}

###### 

Case reports of pancreatic IMT displaying age at time of diagnosis, gender, tumor size and localization, therapy and follow-up

  Reference                        Age (years)   Gender   Tumor size (CT/US)          Localization               Therapy     Follow-up
  -------------------------------- ------------- -------- --------------------------- -------------------------- ----------- --------------------------------------------
  Johnson et al. \[[@B12]\]        29            F        10 cm                       pancreatic head            resection   relapse after 8 months
  Abrebanel et al. \[[@B13]\]      12            F        12 cm                       pancreatic body            resection   2 years, curative
  Scott et al. \[[@B14]\]          2.5           F        13 cm                       pancreatic body            resection   6 years, curative
  Palazzo and Chang \[[@B15]\]     52            F        3 cm                        pancreatic tail            resection   6 months, curative
  Uzoaru et al. \[[@B16]\]         8             F        3 cm                        pancreatic head            resection   4.5 years, curative
  Kroft et al. \[[@B17]\]          39            F        7 cm                        pancreatic body            resection   6 months, curative
  Qanadli et al. \[[@B18]\]        29            M        12 cm                       pancreatic tail            resection   5 months, curative
  Shankar et al. \[[@B19]\]        8             F        10.7 cm                     pancreatic body and tail   resection   2 years, curative
  Petter et al. \[[@B20]\]         64            M        5 cm                        pancreatic head            resection   4 years, curative
  Morris-Stiff et al. \[[@B21]\]   11            M        10 cm                       pancreatic body and tail   resection   3 years, curative
  McClain et al. \[[@B22]\]        11            F        3.4 cm                      pancreatic head            resection   not available
  Liu and Consorti \[[@B23]\]      54            F        5 cm                        pancreatic head            resection   2 years, curative
  Walsh et al. \[[@B24]\]          35            M        5 cm                        pancreatic head            resection   relapse with lung metastasis after 6 years
  Zanger et al. \[[@B25]\]         62            F        4.5 cm                      pancreatic head            resection   6 months, curative
  Yamamoto et al. \[[@B26]\]       55            M        1.5 cm                      pancreatic head            resection   28 months, curative
  Slavotinek et al. \[[@B27]\]     4             F        3 cm                        pancreatic head            resection   4 years, curative
  Esposito et al. \[[@B28]\]       69            M        tumor mass                  pancreatic body and tail   resection   7 months
  Pungpapong et al. \[[@B7]\]      70            M        3.8 cm                      pancreatic tail            resection   10 months, curative
  Wreesman et al. \[[@B29]\]       62            M        3 cm                        pancreatic head            resection   6 years, curative
                                   56            M        not available               pancreatic head            resection   5 years, curative
                                   50            M        5 cm                        pancreatic head            resection   4 years, curative
                                   57            F        not available               pancreatic head            resection   3 years, curative
                                   45            M        no mass lesion identified   pancreatic head            resection   10 years, curative
                                   32            F        2.5 cm                      pancreatic head            resection   12 years, curative
  Stringer et al. \[[@B30]\]       5             F        7 cm                        pancreatic body            resection   9 months, curative
